Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

Viking CEO Brian Lian said during a conference call Tuesday that it's unclear "how durable" the weight loss is. Still, he noted that the sustained weight loss seen in the trial may be encouraging ...

Viking plans to explore monthly dosing for ... for weight loss in the ongoing VENTURE trial for oral VK2735. Brian Lian responded that weight loss trajectories seen in earlier data suggest ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...